Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 18/20 | 0.80 |
| ▸ | GCGR | P47871 | 9/20 | 0.80 |
| ▸ | GIPR | P48546 | 6/20 | 0.80 |
| ▸ | CCKBR | P32239 | 4/20 | 0.69 |
| ▸ | CALCR | P30988 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30460356 | 1.00 | GLP1R (0.80) | GLP1RGCGRGIPRCCKBRCALCR | |
| SCHEMBL30645490 | 1.00 | GLP1R (0.80) | GLP1RGCGRGIPRCCKBRCALCR | |
| SCHEMBL30473764 | 1.00 | GLP1R (0.80) | GLP1RGCGRGIPRCCKBRCALCR | |
| SCHEMBL30205160 | 0.99 | GLP1R (0.81) | GLP1RGCGRGIPRCCKBRCALCR | |
| SCHEMBL31099269 | 0.98 | GLP1R (0.79) | GLP1RGCGRGIPRCCKBRCALCR | |
| SCHEMBL30473786 | 0.98 | GLP1R (0.79) | GLP1RGCGRGIPRCCKBRCALCR | |
| SCHEMBL30473804 | 0.98 | GLP1R (0.79) | GLP1RGCGRGIPRCCKBRCALCR | |
| SCHEMBL31072728 | 0.98 | GLP1R (0.81) | GLP1RGCGRGIPRCCKBR | |
| Exenatide SCHEMBL20509814 | 0.98 | GLP1R (0.81) | GLP1RGCGRGIPRCCKBR | |
| Exenatide SCHEMBL29827241 | 0.98 | GLP1R (0.81) | GLP1RGCGRGIPRCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114456276-A | Preparation method and application of long-acting exenatide | 中国科学院大学宁波华美医院 | 2022-05-10 | — | — | CN | claimed |
| EP-3452049-B1 | GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | IONIS PHARMACEUTICALS INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20250074964-A1 | STABLE GLP-1 ANALOGS FOR THE TREATMENT OF HUMAN DISEASE AND DISORDERS | Ambio, Inc. | 2025-03-06 | — | — | US | disclosed |
| US-20250051405-A1 | EXTENDED RECOMBINANT POLYPEPTIDES AND COMPOSITIONS COMPRISING SAME | AMUNIX PHARMACEUTICALS, INC. | 2025-02-13 | — | — | US | disclosed |
| US-12115225-B2 | GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof | ASTRAZENECA AB (SE) | 2024-10-15 | — | — | US | disclosed |
| US-20240293563-A1 | GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | ASTRAZENECA AB (SE) | 2024-09-05 | — | — | US | disclosed |
| US-12071456-B2 | Extended recombinant polypeptides and compositions comprising same | AMUNIX PHARMACEUTICALS, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| US-20230324389-A1 | COMPOSITIONS AND METHODS RELATED TO ACTIVATABLE THERAPEUTIC AGENTS | AMUNIX PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230303640-A1 | EXENDIN-4 PEPTIDE ANALOGS | TXP PHARMA AG (CH) | 2023-09-28 | — | — | US | disclosed |
| CN-113456820-B | Compositions comprising GLP-1 receptor agonists and glucagon receptor agonists and uses thereof | 派格生物医药(苏州)股份有限公司 | 2023-09-08 | — | — | CN | disclosed |
| CN-113546159-B | Compositions comprising GLP-1 receptor agonists and glucagon receptor agonists and uses thereof | 派格生物医药(苏州)股份有限公司 | 2023-09-08 | — | — | CN | disclosed |
| US-20230158247-A1 | MEDICAMENT DELIVERY DEVICE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2023-05-25 | — | — | US | disclosed |
| CN-114456276-A | Preparation method and application of long-acting exenatide | 中国科学院大学宁波华美医院 | 2022-05-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240293563-A1 | GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | GLP1R, GIPR, GRPR | GLP1R 1/4885GCGR 4/4885GIPR 2/4885 |
| US-20250074964-A1 | STABLE GLP-1 ANALOGS FOR THE TREATMENT OF HUMAN DISEASE AND DISORDERS | GLP1R, GIPR, GPR119 | GLP1R 1/4885GCGR 5/4885GIPR 2/4885 |
| US-12115225-B2 | GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof | GLP1R, GIPR, GRPR | GLP1R 1/4885GCGR 4/4885GIPR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.